By
The Medtech Reev, founded in 2021 between Toulouse and Boston, develops an intelligent robotic orthosis which pushes the limits of traditional exoskeletons. Its flagship device, Dreevenis based on technology adaptive electrohydraulicoffering patients with neurological disorders a Unpublished mobility gain.
Faced with the limits of current – bulky, expensive and rigid – Reev devices offers a lighter and accessible alternative. Associated with Reev Sensea system of connected sensors capable of analyzing the walking in real time, the orthosis adjusts its assistance according to the specific needs of each patient. An approach that aims to modernize the orthotics industry and improve the daily lives of people loss of autonomy.
Reev takes a key step with the Production of the first 100 commercial units of Reev Sense accompanied by FDA medical certifications in the United States in Europe. In parallel, a MIT clinical study made it possible to bring together new data on pathological walking. These advances pave the way to large -scale industrialization.
Strategic funding to accelerate marketing
ReEV announces a lifting of 8.8 million euros To finalize the miniaturization of Dreeven and Launch a pivot clinical study in Boston Universitydecisive step towards obtaining a marketing authorization in the United States and Europe. The round of table was led by Polytechnique Ventures, Newfund Heka and Irdi Capitalwith the participation of Techstars and a pool of business angels gathered by Scala Heritageincluding in particular Raphaël Varane and the Dr Hervé Silbert.
Founded by Amaury Ciurana (CEO) and Robin Temporelli (CTO)ReEV now brings together a team of 30 people Between France and the United States. With a Commercial launch planned in 2026the company aims to impose a new standard in the intelligent medical orthotics sector.
